San Francisco, CA, United States of America

Vandana Mathur

This inventor holds 1 USPTO granted patent. Top assignee: Elan Pharmaceuticals, Inc.. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Vandana Mathur: Innovator in Transdermal Drug Delivery

Introduction

Vandana Mathur is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of pharmaceuticals, particularly in the area of transdermal drug delivery systems. Her innovative work has the potential to improve treatment options for patients with specific medical conditions.

Latest Patents

Vandana Mathur holds a patent for the "Transdermal administration of fenoldopam." This patent describes both the racemic mixture and the active R-fenoldopam enantiomer. It also details transdermal patches designed for the effective therapeutic administration of racemic fenoldopam and its active R-fenoldopam enantiomer. This invention aims to provide treatment for individuals suffering from impaired renal function or hypertension.

Career Highlights

Vandana Mathur is currently associated with Elan Pharmaceuticals, Inc., where she continues to advance her research and development efforts. Her work has garnered attention for its potential to enhance patient care through innovative drug delivery methods.

Collaborations

Some of her notable coworkers include Dawn McGuire and David J. Ellis. Their collaborative efforts contribute to the ongoing success of their projects and innovations within the company.

Conclusion

Vandana Mathur's contributions to transdermal drug delivery represent a significant advancement in pharmaceutical science. Her innovative approach has the potential to improve treatment outcomes for patients with renal issues and hypertension.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…